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The heat-labile toxins (LT) produced by enterotoxigenic Escherichia coli display adjuvant 
effects to coadministered antigens, leading to enhanced production of serum antibod-
ies. Despite extensive knowledge of the adjuvant properties of LT derivatives, including 
in vitro-generated non-toxic mutant forms, little is known about the capacity of these 
adjuvants to modulate the epitope specificity of antibodies directed against antigens. 
This study characterizes the role of LT and its non-toxic B subunit (LTB) in the modulation 
of antibody responses to a coadministered antigen, the dengue virus (DENV) envelope 
glycoprotein domain III (EDIII), which binds to surface receptors and mediates virus entry 
into host cells. In contrast to non-adjuvanted or alum-adjuvanted formulations, antibodies 
induced in mice immunized with LT or LTB showed enhanced virus-neutralization effects 
that were not ascribed to a subclass shift or antigen affinity. Nonetheless, immunosig-
nature analyses revealed that purified LT-adjuvanted EDIII-specific antibodies display 
distinct epitope-binding patterns with regard to antibodies raised in mice immunized 
with EDIII or the alum-adjuvanted vaccine. Notably, the analyses led to the identification 
of a specific EDIII epitope located in the EF to FG loop, which is involved in the entry of 
DENV into eukaryotic cells. The present results demonstrate that LT and LTB modulate 
the epitope specificity of antibodies generated after immunization with coadministered 
antigens that, in the case of EDIII, was associated with the induction of neutralizing 
antibody responses. These results open perspectives for the more rational development 
of vaccines with enhanced protective effects against DENV infections.
Keywords: heat-labile toxins, labile toxins, adjuvants, dengue virus, envelope protein, vaccines, antibodies, 
immunosignature
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inTrODUcTiOn
Adjuvants are essential components of vaccines, particularly 
those composed of purified antigens, which naturally have lower 
immunogenicity than live attenuated microorganisms. Adjuvants 
are known for their ability to enhance the magnitude of adaptive 
immune responses, particularly antibody responses, to coadmi­
nistered antigens; they may impact the longevity, antigen avidity, 
and modulation of isotype and IgG subclass switches (1, 2). 
To date, only a limited number of adjuvants have been incorporated 
into human vaccines, but several different substances, including 
bacterial toxins, are known for their strong and rather versatile 
adjuvant effects in various mammalian hosts (3, 4). We are inves­
tigating the changes in epitope recognition elicited by adjuvants.
Heat­labile toxins (LT) naturally produced by some entero­
toxigenic Escherichia coli strains are enterotoxins endowed with 
potent adjuvant effects when coadministered with purified solu­
ble or particulate antigens after delivery via different parenteral 
or mucosal routes (5–9). LTs, similarly to cholera toxin, are com­
posed of one toxic A subunit with enzymatic ADP­ribosylation 
activity and a B subunit pentamer that binds to host cell receptors 
(10, 11). LT adjuvant effects, as well as those associated with 
in vitro­generated non­toxic LT derivatives, including purified B 
subunits and mutated LT forms, have primarily been ascribed to 
the activation of dendritic cells and B and T lymphocytes, lead­
ing to enhanced mucosal and serum antigen­specific antibody 
responses (6, 12–19). In addition, previous evidence indicated that 
LT derivative may modulate the epitope specificity of antibodies 
raised against coadministered antigen (12). Indeed, adjuvant­
mediated modulation of epitope specificity of antibodies is still a 
poorly understood issue, particularly in situations involving the 
design of vaccines capable of inducing protective immunity to 
various infectious diseases.
Dengue fever is caused by an arbovirus transmitted by 
Aedes aegypti mosquitoes. Fifty to one hundred million people 
are affected by the disease in tropical and subtropical regions 
annually, and thousands are potentially at risk to develop more 
serious side effects, which may lead to death caused by the illness 
(20, 21). The dengue virus (DENV) has an envelope composed 
of a single protein (E) and encodes two other structural (prM 
and C proteins) and seven non­structural proteins (22–24). The 
glycoprotein E is composed of three structural and functional 
domains that mediate the initial steps of the DENV infectious 
cycle. Receptor binding is mainly triggered by domain III [enve­
lope glycoprotein domain III (EDIII)], which leads to the sub­
sequent entry and replication of virus into susceptible host cells 
(22, 24, 25). EDIII­specific antibodies can confer protection to 
DENV infection and have been considered protection correlates 
for anti­DENV vaccines (26–31). Nonetheless, depending on the 
specificity, concentration and affinity of antibodies targeting the 
E protein, antibodies may either block virus infection or promote 
enhancement of infection (the antibody-dependent enhancement 
effect—ADE) via cell entry mediated by Fc­γ receptors (32–35).
Proteomics platforms such as microarrays have been exploited 
as promising high­throughput assays to measure humoral immune 
responses, assisting our understanding of the subtle characteris­
tics of successful immunization, a key challenge in the rational 
development of effective vaccines (36–38). The immunosignature 
technology is a microarray­based platform that uses unnatural 
randomized­sequence peptides, spotted in high density, as a 
universal and robust assay to identify antibody­binding patterns 
of natural or induced responses in both humans and mice. Due to 
its successful applicability for both infectious and non­infectious 
diseases, this platform can be used as a powerful tool for system­
atic studies of various vaccine approaches (39–46).
In this study, we compared the adjuvant effects of alum, LT and 
LTB in vaccine formulations containing a recombinant form of the 
DENV EDIII antigen. The results demonstrate that, in contrast 
to mice immunized with the alum­adjuvanted formulation, mice 
parenterally immunized with EDIII admixed with LT or LTB 
mounted a more efficient antibody response capable of inhibit­
ing DENV infection. Immunosignature analysis of the humoral 
immune response elicited in vaccinated mice showed that LT dif­
ferentially modulates the epitope specificity of the EDIII­specific 
IgG antibodies. In addition, the results led to the identification of 
an EDIII­derived peptide specifically involved in the infectivity 
of the virus into host cells. Together, this study emphasizes the 
role of adjuvants in the modulation of the epitope specificity of 
antibodies induced upon vaccination and, thus, may impact the 
development of anti­DENV and other subunit vaccines.
MaTerials anD MeThODs
cloning of adjuvant lTB
LTB was obtained after cloning the nucleotide sequence of the 
eltB gene (encoding the B subunit of the LT from H10407 strain) 
into the pET22b vector. The eltB sequence (450 bp) was amplified 
by PCR using the forward primer 5′­CAGAAGGCGGAATGA 
CATATGAATAA­3′ and reverse primer 5′­TTAAAAGCATGT 
CTCTCGAGAGAACC­3′ (the underlined sequences indicate 
the NdeI and XhoI restriction sites, respectively). The insert 
generated by the PCR reaction was digested and ligated into the 
corresponding NdeI and XhoI restriction sites of the pET22b 
expression vector (Novagen­Merck Bioscience, MA, USA), 
generating the recombinant plasmid pET22bLTB, which was 
subsequently used to transform chemically competent E. coli 
DH5α. Transformants were analyzed by digestion with the 
enzymes NdeI and XhoI. The recombinant DNA fragment was 
sequenced and compared to data reported for the LT sequence 
(GenBank database GI: 408994). A chemically competent E. coli 
BL21 (DE3) strain was transformed with the pET22bLTB plasmid 
and denominated as E. coli BL­LTB.
expression and Purification of adjuvants
The LT and LTB adjuvants were obtained from E. coli strains har­
boring the plasmid pML19 (47, 48) or pET22bLTB, respectively. 
The purification of LT was based on a previously described method 
(47). The recombinant E. coli strains were cultivated in Luria­
Bertani (LB) medium or Terrific Broth (TB) supplemented with 
100 µg/ml of ampicillin at 37°C in an orbital shaker (200 rpm). 
While LTB expression was obtained after 0.75 mM IPTG induc­
tion of the E. coli BL­LTB strain cultures for 6 h, LT production was 
achieved by constitutive expression of the eltAB gene in overnight 
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cultures of a pML19­harboring E. coli strain. The cell pellets were 
suspended, and the bacterial cells were disrupted by high pres­
sure in a homogenizer (APLAB­10 model, ARTEPEÇAS, Brazil). 
The LT and LTB contained in the bacterial cell homogenates were 
purified by affinity chromatography on immobilized d­galactose 
columns (Pierce, Waltham, MA, USA) previously equilibrated with 
TEAN buffer (50 mM Tris, 1 mM EDTA, 3 mM NaN3, and 0.2 M 
NaCl, pH 7.4) in an Akta FPLC (Amersham Pharmacia Biotech, 
Buckinghamshire, UK). The elution step was performed with 
TEAN supplemented with 0.3 M d­galactose. The proteins were 
monitored by 15% sodium dodecyl sulfate­polyacrylamide gel 
electrophoresis (SDS­PAGE). The concentrations of the purified 
proteins were determined by absorbance measurements in a spec­
trophotometer (Gene Quant spectrophotometer GE Amersham 
Biosciences, Buckinghamshire, UK) as previously described (49).
cloning, expression, and Purification of 
antigen
The pE1D2 plasmid (50), harboring gene encoding the ectodo­
main of the envelope glycoprotein from the DENV2 New Guinea 
C (NGC) strain, was kindly provided by Dr. Ada Alves and used as 
template for PCR reactions. The sequences of the forward and reverse 
primers used in PCR reactions were 5′­ACATGCGAGGATCCG 
GAATGTCATACTCTAT­3′ (the underlined sequence indicates 
the BamHI restriction site) and 5′­GCCTTCTACTCGAGTTAC 
GATAGAACTTCCTTTCTTA­3′ (the underlined sequence indi­
cates the XhoI restriction site), respectively. The PCR product 
was introduced into pET28a(+) expression vector (Novagen, 
Germany), generating the recombinant plasmid pDEDIII. The 
E. coli BL21 (DE3) strain harboring the plasmid pDEDIII was 
cultivated in LB medium containing 50 µg/ml kanamycin. The 
culture at an OD600nm of 0.5 was induced by IPTG to a final concen­
tration of 0.5 mM and incubated for 4 h. The bacterial pellet was 
suspended in buffer A (0.1 M Na2PO4, 0.5 M NaCl, pH 6.8) and 
lysed in the APLAB­10 homogenizer (ARTEPEÇAS, Brazil). The 
inclusion bodies were solubilized in buffer A supplemented with 
8 M urea, and the recombinant protein was refolded in buffer A. 
The soluble protein was submitted to nickel affinity chromatogra­
phy using a HisTrap™ HP column (GE Healthcare Life Sciences, 
Buckinghamshire, UK). The purified EDIII was evaluated by 15% 
SDS­PAGE and measured by spectrophotometry.
endotoxin removal from Purified Protein 
Preparations
The endotoxin was removed using a Detoxi­gel Endotoxin 
Removing Gel (Pierce, Waltham, MA, USA), and any residual 
endotoxin was detected by the Limulus Amebocyte Lysate (LAL) 
QCL 1000 kit (Lonza, Basel, Switzerland). Following treatment 
for LPS removal, the residual endotoxin contents in the LT, LTB, 
and EDIII samples were less than 0.1 EU/μg of protein, corre­
sponding to the levels allowed for preclinical research (51).
Biological characterization of lT and  
lTB adjuvants
The cytotonic activity of the LT derivatives on the adrenal Y1 
cells was evaluated as previously described (6). The Y1 cells 
were seeded in 96­well plates (5 × 104 cells/well) and exposed 
to 1 µg of LT or LTB, or to phosphate­buffered saline (PBS) as 
negative control, diluted in Dulbecco’s modified Eagle’s medium 
(DMEM, Vitrocell Embriolife, Brazil) supplemented with 2% 
fetal bovine serum (FBS, Vitrocell Embriolife, Brazil). After 8 h 
of incubation, the cells were observed for the cytotonic effect. 
The GM1­ELISA was performed as previously described (52) to 
evaluate LT binding to the cognate ganglioside GM1. Microtiter 
plates (Polysorp, Thermo Fisher­Nunc, Roskilde, Denmark) 
were coated with GM1 ganglioside (1 µg/ml) (Sigma­Aldrich, 
St. Louis, MO, USA) diluted in PBS (pH 7.4) and incubated 
overnight at room temperature in a humid chamber. Plates were 
blocked with PBS containing 0.1% BSA. Then, serially twofold 
diluted LT samples were applied in duplicate wells. To detect 
LT derivatives, the plates were sequentially incubated with 
anti­LT serum (titer equal to 105) and horseradish peroxidase 
(HRP)­conjugated anti­mouse IgG antibodies (Sigma­Aldrich) 
diluted to 1:1,000 and 1:3,000, respectively, in PBS containing 
0.05% Tween­20 and 0.1% BSA. The chromogenic reactions 
developed with ortho­phenylenediamine dihydrochloride 
(Sigma­Aldrich) and H2O2 were stopped with 1 M H2SO4 and 
measured at A492nm.
analysis of the Biological activity  
of recombinant eDiii in Vero cells
This assay was performed as previously described (53). African 
Green Monkey Kidney Epithelial Cells (Vero Line), which express 
receptors for E glycoprotein, were cultured in minimum essential 
medium (MEM) supplemented with 2% FBS and incubated at 
37°C in an atmosphere containing 5% CO2 for 24 h. Cells were 
incubated with 100 µg/ml of EDIII protein in MEM at 37°C in 5% 
CO2 for 30 min. After washing with PBS with 2% FBS, Vero cells 
were fixed with 4% paraformaldehyde (Sigma­Aldrich, St. Louis, 
MO, USA) for 10 min, treated with anti­EDIII sera harvested from 
mice immunized with EDIII plus Freund’s adjuvant for 60 min 
and subsequently with goat anti­mouse IgG conjugated to FITC 
(Invitrogen, Paisley, UK) for further 60 min. The FITC­stained 
Vero cells were detected by BD LSRFortessa flow cytometry (BD 
Bioscience, San Jose, CA, USA), and the data were analyzed using 
the FlowJo v10 program.
animal immunizations
All experiments involving mice were approved by the Committee 
on the Ethical Use of Laboratory Animals of the Institute of 
Biomedical Sciences (CEUA 198) at the University of São Paulo 
(USP), in accordance with the guidelines for the care and use of 
laboratory animals adopted by the National Council of Animal 
Experimentation (CONCEA). The mice were obtained from the 
Isogenic Mouse Breeding Facility of Department of Parasitology, 
Institute of Biomedical Sciences—USP. Female BALB/c mice 
(6–8  weeks old) were immunized via the subcutaneous (s.c.) 
route at days 0, 14, and 28 of the immunization protocol with the 
vaccine formulations. Groups of five BALB/c mice were treated 
with 100 µl of PBS alone as a negative control or PBS containing 
10 µg of EDIII with or without one of the following adjuvants: 
1.0 µg of LT, 3.2 µg of LTB, or 12.5 µg of Al(OH)3 (Rehydragel, 
Reheis, NJ, USA). Serum samples were harvested 2 weeks after 
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each vaccine dose and stored at −20°C until immunological 
analyses were conducted.
elisa
ELISA for anti­EDIII antibodies was performed as previously 
described (53). Microtiter plates (Maxisorp Thermo Fisher­
Nunc, Roskilde, Denmark) were coated with EDIII (1  µg/ml) 
diluted in PBS pH 7.4 and incubated overnight at 4°C. For ELISA 
using denaturing conditions, the EDIII protein was submitted to 
heat treatment at 100°C for 15 min and used to coat the plates. 
Plates were blocked with PBS containing 3% gelatin for 2  h at 
37°C. The serum samples harvested from mice immunized with 
EDIII alone or coadministered with each adjuvant were applied 
to duplicate wells and serially twofold diluted. The serum IgGs 
were measured with HRP­conjugated anti­mouse IgG (1:3,000), 
IgG1 (1:10,000), or IgG2a (1:3,000) antibodies (Sigma­Aldrich, 
St. Louis, MO, USA). Absorbance at 492  nm was obtained as 
previously described and used to calculate the antibody titers, 
defined as the highest sample dilution able to generate an A492nm 
of 0.2 above the preimmune sera.
Purification of serum igg Fractions
Anti­EDIII IgG antibody fractions were obtained from serum 
samples harvested from mice submitted to EDIII­based immuni­
zation regimens. First, the recombinant 6×­His­tagged EDIII was 
immobilized in a column filled with a nickel­coupled resin. After 
serum delipidation, as previously described (54), the sera were 
submitted to affinity chromatography on EDIII­immobilized 
resin using 0.05 M PBS, pH 7.4. The anti­EDIII antibodies were 
eluted in 0.1  M glycine buffer (pH 4), neutralized with 1  M 
Tris–HCl (pH 9.0), and dialyzed in PBS (pH 7.4). Subsequently, 
the anti­EDIII antibodies were subjected to affinity chromatog­
raphy to protein G sepharose according to the manufacturer’s 
instructions (GE Healthcare, Buckinghamshire, UK), and the 
IgG fraction was obtained following the elution step described 
above. The purified EDIII­specific IgG antibodies were measured 
by BCA assay (Pierce, Waltham, MA, USA) and monitored by 
12.5% SDS­PAGE.
affinity assay for anti-eDiii igg antibodies
The antibody affinity index was measured using a modified ELISA 
protocol with ammonium thiocyanate (47). Briefly, the plates were 
coated with EDIII as described above. The sera collected from 
mice from different immunization groups were tested at dilutions 
corresponding to an OD492nm of 0.8, while purified anti­EDIII IgG 
antibodies were evaluated at an OD492nm of 0.5. After incubation 
with sera or purified antibodies, different concentrations of 
sodium thiocyanate were added to wells and incubated for 15 min. 
The plates were washed and incubated with HRP­conjugated 
anti­mouse IgG antibody. The percentage of antibodies bound to 
EDIII was determined: OD492nm in the presence of ammonium 
thiocyanate ×  100/OD492nm in the absence of ammonium thio­
cyanate. The values obtained with the serum samples represent 
the antibody avidity, which under our conditions depends on the 
affinity and valence of the immunoglobulins since the parameter 
of structural arrangement was standardized by the use of the 
antigen immobilized on the solid support. The analyses of the 
purified IgG antibodies showing constant Ig valence generated 
average affinity values for each immunization group.
Plaque reduction neutralization  
Test (PrnT)
To perform the PRNT, the DENV2 NGC strain, kindly provided 
by Laura Helen Vera Gonzales Gil (Fiocruz, Recife, Brazil), 
was purified, and the Vero cells were cultivated as previously 
described (35). Briefly, the NGC strain was propagated in the 
Aedes albopictus cell line C6/36 cultured in Leibovitz medium 
containing 5% FBS and grown at 28°C for 7 days. The superna­
tant of C6/36 infected with the NGC strain was collected and 
titrated for the determination of PFU/ml. For the neutralization 
test, Vero cells were maintained in DMEM supplemented with 
10% FBS and seeded in 24­well plates (1 × 105 cells/well) 24 h 
before infection. Serum samples from immunized mice were 
inactivated for complement proteins for 30  min at 56°C and 
serially twofold diluted. Purified EDIII­specific IgGs were tested 
at different concentrations. C6/36 cell supernatants contain­
ing 500 PFU of DENV/ml were incubated with each dilution 
of anti­EDIII sera or purified IgG antibodies for 1  h at 37°C. 
Vero cells were washed with serum­free DMEM and infected 
in duplicate wells with 200 µl of the neutralization mixture for 
1  h at 37°C. The viral suspension was removed, and the cells 
were overlaid with 1 ml of complete DMEM [2.5% FBS and 1% 
carboxymethylcellulose (Synth, São Paulo, Brazil)]. Following 
incubation of the plates at 37°C for 7 days, the cells were fixed 
for 15 min with 4% paraformaldehyde and stained with crystal 
violet for 10 min. The percentage of plaque reduction compared 
to the positive control (DENV not exposed to antibodies) was 
calculated. Neutralizing antibody titers were expressed as the 
serum dilution, or IgG concentration, yielding 50% plaque 
number reduction (PRNT50).
immunosignature assay
For the peptide microarray assay, slides were manufactured 
using in  situ synthesis of 330,000 (CIM330K) sequences of 
non­natural randomized peptides as previously described (40). 
Statistical analyses of microarray data were performed using 
JMP 12 software (Statistical Discovery Software from SAS) by 
importing data analysis from Excel and image­processed data 
from GenePix Pro­6.0 (Molecular Devices, Sunnyvale, CA, 
USA). Raw intensities were normalized to each slide by divid­
ing all values per array by the median of that array (median 
normalization). Poor quality spots were excluded from analysis 
by flagging them as “absent” upon visual inspection. Values 
less than 0.01 were set to 0.01, and values from duplicate arrays 
were averaged and used in the analysis. Important peptides were 
determined by Student’s two­tailed t­test, with Benjamini and 
Hochberg multiple test correction applied to a p value < 0.05. 
For principal component analysis, we used significant peptides 
for each vaccine approach and an analysis using JMP 12 soft­
ware (39). The prediction of recognized epitopes was based on 
lists of informative peptides compared to the EDIII sequence 
from the DENV2 strain NGC (AHG97599.1) using GuiTope 
(55). The amino acid substitution matrix was provided by the 
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peptide library and protein sequence. An inversion weight of 
1 was selected. Library subtracted scores were returned using 
the mean of 10 random samplings of the peptide library and a 
minimum score cutoff of 8.0. The results were graphed using 
GraphPad Prism v5 using a moving average of 15.
competition assay for DenV2 Using 
Peptides
This assay was adapted from a protocol previously described (56, 57). 
Vero cells (1 × 105 cells/well, on 96­well plates) were cultured in MEM 
supplemented with 3% FBS and incubated at 37°C in an atmosphere 
containing 5% CO2 for 18 h. Intact or heat­denatured EDIII pro­
tein, as well as peptide 47 (369­AEPPFGDSYIIIGVEPGQLK­388), 
custom­made by GeneScript (Piscataway, NJ, USA), at different 
molar concentrations, was incubated with the DENV2 strain 
NGC (multiplicity of infection—equal to 1.0). The mixtures were 
added to Vero cells at 37°C in 5% CO2 for 1 h. The mixtures were 
removed, and MEM supplemented with 2% FBS was added to each 
well. Following 18 h of incubation, the culture plates were washed 
with PBS and treated with 50 µl/well of trypsin (2.5 mg/ml) plus 
EDTA at 37°C in 5% CO2 for 10 min to remove the cells. Vero 
cells were resuspended with PBS containing 10% FBS and fixed 
and permeabilized with Cytofix/Citoperm kit (BD Bioscience, 
San Jose, CA, USA) for 10 min. The cells were incubated for 1 h 
with mAb 4G2, which recognizes the fusion loop at the extremity 
of the domain II of the envelope protein (ATCC­HB112), and 
subsequently labeled with anti­mouse IgG conjugated with Alexa 
488 (BD Biosciences) for 30 min. The stained cells were measured 
by flow cytometry using a BD LSRFortessa (BD Bioscience, 
San Jose, CA, USA) instrument, and the data were analyzed with 
FlowJo v10 software to determine the amount of DENV­positive 
Vero cells. Viral replication analysis was carried out at 24 h post­
infection based on a protocol previously described (58). RNA 
was extracted from 100 µl of infected Vero cell, using a guanidine 
isothiocyanate phenol method (Trizol LS, Invitrogen), according 
to the manufacturer’s instructions. The quantitative real­time 
polymerase­chain­reaction was carried out with a set of primers 
and probes with FAM as dye reporter for the probe. Primers/
probes used in assay for DENV were previously described (58). 
The assay was performed using the AgPath­IDTM One­Step 
RT­PCR reagents (Applied Biosystems). Succinctly, we used 
5 µl of the extracted RNA in 1 µl of the mix from primers/probe 
(10 pM/μl) and 19 µl of the reagent mix from AgPath­IDTM One­
Step RT­PCR kit following the manufacturer’s instructions.
structural analyses
The amino acid sequence composing the main predicted epitope 
was indicated in a previously published structural model of the 
quaternary DENV2 envelope glycoprotein (PDB accession num­
ber 1OKE) using PyMol v1.8.4.0.
statistical analyses
The data are represented as arithmetic means ± SD and analyzed 
for variance (ANOVA) with a subsequent Bonferroni’s multiple 
comparison test using GraphPad Prism v5 software. For the 
data generated by the PRNT and affinity assay, the statistical 
analyses were calculated from two independent experiments, 
while all other results were analyzed from three independent 
experiments.
resUlTs
lT and lTB enhance eDiii-specific 
antibody responses
The recombinant forms of LT, LTB and type 2 DENV EDIII 
were purified by affinity chromatography (Figures S1 and S2 in 
Supplementary Material). Both LT and LTB bind to host cell 
receptors, but as expected, only LT had cytotonic effects to Y1 
cells (Figures S1C,D in Supplementary Material). The recombi­
nant EDIII also preserved the receptor­binding function of the 
native viral protein (Figure S2B in Supplementary Material). 
Mouse groups were immunized with purified EDIII and vaccine 
formulations containing EDIII admixed with alum, LT, or LTB. 
Mice received three s.c. doses at intervals of 2 weeks and were 
bled one day before each dose and 2 weeks after the last vaccine 
dose (Figure 1A). Significant increases in the EDIII­specific IgG 
antibody levels were detected in serum samples of mice immu­
nized with vaccines containing LT and LTB, but not with alum 
compared to EDIII alone (Figures  1B,C). The antigen­specific 
IgG1/IgG2a ratios in vaccinated mice were similar, indicating 
that the adjuvants were not able to modulate the IgG subclass 
responses induced by the antigen alone. Although anti­EDIII 
IgG1 and IgG2a titers detected in mice immunized with LT and 
LTB enhanced in comparison with the non­adjuvanted EDIII, 
significant differences were only found regarding to IgG1 levels 
(Figure  1D). In addition, EDIII­specific antibodies in serum 
samples collected from vaccinated mice were capable of recogniz­
ing both conformational and linear epitopes of the antigen, as 
demonstrated by reactivity with both intact and heat­denatured 
antigen. Serum samples from mice immunized with LT or LTB 
showed significantly higher reactivity with both conformational 
and linear epitopes than those collected from mice immunized 
with non­adjuvanted EDIII or EDIII admixed with alum 
(Figures 1E,F).
antigen reactivity and  
DenV-neutralization Properties of  
Purified eDiii-specific antibodies
To evaluate the role of adjuvants in the modulation of the effec­
tor activities of antigen­directed antibodies induced by subunit 
vaccines, EDIII­specific antibodies raised in different mouse 
groups were purified by affinity chromatography (Figure S3 in 
Supplementary Material). The purified anti­EDIII antibodies 
reacted with the native antigen but did not recognize the 
heat­denatured antigen, suggesting that the purified antibod­
ies are specifically directed toward conformational epitopes 
(Figure 2A; data not shown). No difference in antigen affinity 
was detected in EDIII­specific antibodies raised in the different 
immunization groups (Figure 2B). Anti­EDIII antibodies, either 
in serum or purified fractions from vaccinated mice showed 
virus­neutralization activity in vitro; however, anti­EDIII anti­
bodies elicited with LT or LTB were more efficient than those 
FigUre 1 | Analysis of envelope glycoprotein domain III (EDIII)-specific antibody responses induced in mice immunized with different vaccine formulations.  
(a) Schematic representation of the vaccine regimen tested in this study. BALB/c female mice were s.c. immunized with three doses of EDIII alone (10 µg) or EDIII 
coadministered with one of the tested adjuvants [LT1 (1 µg), LT1-B (3.2 µg), or alum (12.5 µg)]. (B) Analyses of the antigen-specific IgG responses performed in 
blood samples collected 2 weeks after each vaccine dose. (c,D) Evaluation of the anti-EDIII total IgG (c) or IgG subclass (D) responses was carried out 2 weeks 
after the third dose. (e,F) Reactivity of serum antibodies carried out by ELISA with the native purified EDIII antigen (e) or the same antigen submitted to a heat 
denaturation treatment (F) used as solid phase bound antigens. Anti-EDIII titers were determined in three independent experiments with at least five animals per 
immunization group. Values represent means ± SD of the IgG titers. ***p < 0.001, **p < 0.01, and *p < 0.05, comparing adjuvanted EDIII-immunized mice to 
non-adjuvanted EDIII-immunized mice or alum-adjuvanted mice (ANOVA with Bonferroni post hoc test).
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FigUre 2 | Characterization of purified envelope glycoprotein domain III (EDIII)-specific IgG antibodies raised in mice immunized with different adjuvants.  
(a) Reactivity of antibodies with the purified antigen following ELISA. (B) Affinity of purified antibodies to the purified EDIII antigen. Values are expressed by 
percentage of antibodies that remain bound to the solid phase-adsorbed antigen under presence of ammonium thiocyanate in regard to the reaction performed 
without ammonium thiocyanate. Immunization groups represented by different symbols as indicated in the insert. (c,D) Plaque reduction neutralization test of a 
DENV2 strain (New Guinea C) carried out with serially diluted serum samples (c) or various amounts of purified EDIII-specific IgG antibodies (D) derived from mice 
immunized with the different vaccine formulations, as indicated in panel (B). Results are based on two independently performed experiments carried out with 
duplicate samples. Values represent means ± SD. ***p < 0.001, **p < 0.01, and *p < 0.05, significant differences with regard to mice immunized with non-
adjuvanted EDIII (two-way ANOVA with Bonferroni post hoc test). NS: values without statistically significant differences.
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raised with antigen alone or admixed to alum (Figures 2C,D; 
Table S1 in Supplementary Material). The mice immunized 
with LTB coadministered to EDIII elicited antigen­specific sera 
with twofold higher neutralizing capability than LT­adjuvanted 
vaccination (Figure 2C; Table S1 in Supplementary Material). 
The purified anti­EDIII IgG from both LT and LTB­adjuvanted 
mice yielded neutralization titers (PRNT50) of 1.6  ng/ml and 
thereby revealed strong virus­neutralizing effects (Figure 2D).
immunosignatures of anti-eDiii antibodies
To gain a better understanding of the enhanced virus­ 
neutralization activity of the anti­EDIII antibodies raised in 
mice immunized with different vaccine formulations, we deter­
mined the immunosignatures of purified EDIII­specific anti­
bodies raised in different immunization groups (Figure 3). By 
profiling the antibodies with random linear peptide sequences 
spotted on microarray slides, we observed that antibodies 
from mice immunized with EDIII and LT or LTB had distinct 
immunological signatures for those raised in mice immunized 
without adjuvant or with alum (Figures  3A,B). In addition, 
fewer peptides were recognized with high binding intensity 
by EDIII­specific IgGs adjuvanted with LT or LTB, suggesting 
an increased specificity of these antibodies (Figures  3A,C). 
Analysis of peptide­binding profiles indicated that antibodies 
raised in mice immunized with LT and LTB reacted with 119 
peptides sequences each, while antibodies raised in mice immu­
nized only with antigen, or with alum admixed with the antigen, 
reacted with 605 and 603 peptides, respectively. Among these 
peptides, only 10 were solely recognized by antibodies raised 
in mice immunized with LT or LTB and 88 peptides among all 
groups (Figure 3C).
epitopes Predicted by immunosignatures 
are critical for DenV infection
Prediction of epitopes present in the EDIII antigen and recog­
nized by the different set of purified IgG antibodies showed that 
mice immunized with both LT derivatives reacted with a specific 
sequence comprising the EF loop, F beta­sheet, and FG loop 
between amino acid residues 371–384 (Figures 3D and 4A,B). 
To further investigate the biological relevance of this finding, 
we tested a 21­mer synthetic peptide encompassing the complete 
predicted epitope of the EDIII antigen (Figure 4B). As shown in 
Figure 4C and Figure S4 in Supplementary Material, the peptide 
(EDIII369–388) efficiently blocked the infectivity of DENV2 NGC 
FigUre 3 | Immunosignature analyses of purified envelope glycoprotein domain III (EDIII)-specific IgG antibodies. (a) Heat map demonstrating the immunosignatures 
detected with EDIII-specific IgG antibodies purified from serum samples collected from mice submitted to the different immunization regimens and a mock mouse 
group (control). A Student’s t-test (p < 3.33 × 10−6) between vaccine groups was used to select the informative peptides. Hierarchical clustering using EUCLIDEAN 
distance was used as a measure of similarity to cluster the selected peptides (x axis) and vaccine groups (y axis). Peptides’ intensity is colored where blue 
corresponding to low intensity and red to high intensity. (B) Variance of immune responses among different vaccine groups. Variation among vaccine groups [pooled 
sera per group (n = 5)] for all significant peptides sequences in the principal component analysis plot, where the first two principal components are plotted and 
individuals are colored according to the vaccination groups. (c) Venn diagram between vaccine groups. Results summarize the overlapping peptides that are 
significantly different above 1.3-fold change of the mock group versus each vaccine group. (D) Antigenic epitope prediction for vaccine groups using random peptide 
arrays. Significant peptides sequences recognized by antibodies of each vaccine group were submitted to epitope prediction with the GuiTope software and using 
the EDIII protein sequence from DENV2 New Guinea C (AHG97599.1) as reference. Each line graph represents the GuiTope prediction score for each vaccine group.
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strain in Vero cells. A similar inhibition of DENV infectious 
activity was achieved with the purified EDIII antigen, whereas 
the heat­denatured antigen lost the virus­infection inhibitory 
effect.
DiscUssiOn
A considerable amount of information regarding the use of 
bacterial toxins such as LT as vaccine adjuvants has accumulated 
FigUre 4 | Identification of a linear envelope glycoprotein domain III (EDIII)-derived epitope involved in binding of DENV2 to host cells. (a) 3D representation of DENV E 
protein dimer. Domains I (yellow), II (red), and III (blue) are highlighted. The insert displays EDIII structural features. The amino acid sequence marked in light blue 
encompasses the epitope recognized by antibodies raised in mice immunized with labile toxins (LT)-adjuvanted vaccines. (B) Amino acid sequence of DENV2 EDIII 
(GenBank accession number: AF038403.1). The positions of the EDIII β strands are indicated above the sequence by dark blue arrows, while the sequences of the 
synthetic peptide used in the competition assays are shown below. The epitope predicted by the immunosignature is marked in light blue. (c) Inhibition of DENV2 
infection. Different molar concentrations of synthetic peptide 47 were mixed with DENV2 New Guinea C and subsequently added to cells. Purified EDIII and heat-
denatured EDIII were used as positive and negative controls in the inhibition of virus infectivity assay, as indicated in the figure. Cells stained with primary mAb 4G2 and 
subsequently with Alexa 488-conjugated anti-mouse IgG were measured by cytometry, and the number of DENV-positive infected Vero cells was determined for each 
group. Values express the reduction in the percentage of the number of virus-infected cells compared to the control group denatured EDIII- (untreated DENV2). Dashed 
line indicates 50% inhibition of virus infection. Bars represent the mean values and SEM from three independent experiments. ***p < 0.001, **p < 0.001, and *p < 0.05 
represent significant differences with regard to denatured EDIII-treated and untreated DENV2 (two-way ANOVA with Bonferroni post hoc test).
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during the last four decades. Nonetheless, perspectives on the 
clinical use of non­toxic LT derivatives have been overshadowed 
by the induction of undesirable side effects (transient facial 
paralysis) observed in patients submitted to intranasal immu­
nization trials (59). However, recent observations describing 
the successful use of LT derivatives as parenterally administered 
adjuvants rekindled interest in these adjuvants under both 
experimental and clinical conditions (8, 9, 60–62). In this study, 
we evaluated the adjuvant properties of LT and a non­toxic 
derivative composed of the B subunit pentamer as parenterally 
delivered adjuvants admixed with a recombinant form of the 
DENV2 EDIII. Our results demonstrated that, unlike alum, LT 
and LTB enhanced antibody responses to EDIII and induced the 
generation of antibodies with increased capacity to neutralize 
DENV2 particles. In addition, we demonstrated that both LT 
and LTB drastically changed the epitope­binding profiles of 
EDIII­specific IgG antibodies. Immunosignature analyses per­
formed with peptide microarrays led us to identify an epitope 
located between the EDIII EF and FG loops, which is specifically 
recognized by antibodies raised in mice immunized with LT 
or LTB but not by antibodies raised in mice immunized with 
alum­adjuvanted EDIII or non­adjuvanted antigen. Remarkably, 
a synthetic peptide encompassing the epitope identified by the 
immunosignature analyses interfered with the infectivity of 
DENV2 in mammalian cells, opening perspectives for therapeu­
tic and preventive interventions. Collectively, this study demon­
strated that LT derivatives can modulate the epitope specificity of 
antibodies after parenteral immunization with purified proteins 
and thus may contribute to the rational design of subunit vac­
cines for DENV and other infectious agents.
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The evidence presented here demonstrates that LT used as 
a parenteral adjuvant promotes strong neutralizing antibody 
responses to DENV infection. Antibody neutralization titers 
achieved in mice immunized with EDIII and LT or LTB were 
significantly higher than those elicited in mice immunized with 
alum. In accordance with these findings, the EDIII­specific IgG 
fraction purified from mice immunized with LT or LTB showed 
greater virus­neutralizing activity than antibodies purified from 
mice immunized with alum. Furthermore, purified IgG col­
lected from mice immunized with LT or LTB revealed a strong 
virus­neutralizing effect compared to the previously described 
anti­EDIII mAbs, such as 2H12, 9D12, and 1A1D­2 that block 
DENV infection under in vitro conditions with different intensity 
(26, 32, 63, 64). The results emphasize the fact that parenterally 
administered LT represents a promising adjuvant alternative 
comparable to the most potent adjuvants presently in use under 
both experimental and clinical conditions. In addition, the obser­
vation that purified LT B subunits exert similar adjuvant effects as 
LT indicated that the local inflammatory reactions induced by the 
enzymatically active toxin can be abrogated without reducing the 
immunomodulatory effects to coadministered antigens.
Our results obtained with purified IgGs demonstrated that 
the specificity, and not the magnitude, of the antibody response 
is critical in virus neutralization. In fact, antibody­mediated 
virus­neutralization activity has been strongly correlated with 
antibody/antigen interaction force and/or epitope recognition 
patterns (12, 26, 47). In our case, the distinct neutralization effects 
of the EDIII­specific polyclonal antibodies were not associated 
with antigen affinity. In accordance with these results, several 
studies have reported that the virus­neutralizing activity of anti­
EDIII mAbs or sera does not necessarily correlate with antigen 
affinity (33, 35, 64–67). However, epitope recognition patterns 
of EDIII­specific mAbs showed a positive correlation with virus­
infection blockage activity (26, 32–34, 65). In this context, we 
demonstrated that the immunosignature patterns of antibodies 
raised in mice immunized with LT derivatives differed drastically 
from those raised in mice immunized with non­adjuvanted EDIII 
or alum­adjuvanted antigen. More importantly, such differences 
correlated with an enhanced virus­neutralizing activity of the IgG 
antibodies induced by LT forms. Although corroborative evidence 
remains to be gathered, this study clearly demonstrated that 
adjuvant­mediated modulation of epitope recognition patterns 
by the antibodies raised is a critical aspect of vaccine­induced 
immune responses, particularly with regard to the induction of 
immunity to DENV.
In this report, the immunosignature analyses of EDIII­
specific polyclonal antibodies disclosed that, in contrast to alum, 
incorporation of LT or LTB to vaccine formulation resulted in 
antibodies with increased specificity to the epitopes located 
at the EDIII EF and FG loops in addition to the F β­strand. 
In support of this concept, our study demonstrated that a 
synthetic peptide comprising the predicted epitope interfered 
with the in  vitro infectivity of DENV, as measured with Vero 
cells. In addition, the lateral FG loop has been implicated in 
DENV infectivity both in mosquito and mammalian cells 
(57, 68, 69). More importantly, part of the EDIII epitope unveiled 
by the immunosignature analyses, comprising the F β­strand 
and FG loops, has also been identified as a target epitope for 
anti­DENV and anti­ZIKV mAbs isolated from high responders 
in clinical studies with ZIKV­infected individuals (70). Together, 
these findings emphasize the relevance of the EDIII lateral ridge 
region as a target for antibodies capable of conferring protection 
from flaviviruses.
The role of LT derivatives, in the context of active immuniza­
tion practices, on the modulation of epitope recognition profiles 
of antibodies has been scarcely investigated. Here, and in previ­
ous reports, we have demonstrated that LT derivatives shape the 
epitope recognition profile of antibodies to different pathogens 
[(12), unpublished data]. Previous studies have demonstrated 
that LT derivatives improve the expression of co­stimulatory mol­
ecules on B lymphocytes and dendritic cells and, consequently, 
on prime CD4+ T cells, leading to modulation of Th1/Th2/Th17 
cytokine production patterns (12, 17, 19, 71–73). Although future 
studies will have to be performed, the capacity to program B cells 
using cognate T helper lymphocytes, concomitant with direct 
activation effects, may represent possible alternatives to explain 
the action of LT derivatives on the modulation of the epitope 
recognition pattern of antibodies.
Synthetic peptides have been largely exploited in therapeutic 
approaches against viral diseases such as hepatitis, acquired 
immunodeficiency syndrome and influenza (74). However, little 
effort has investigated the use of peptides for treatment of arbo­
viroses. Anti­dengue peptides under pre­clinical evaluation were 
designed after in silico analyses and target the stem region, hydro­
phobic pocket or FG loop of the E glycoprotein (57, 69, 75, 76). 
These peptides showed half­maximal inhibitory concentration 
(IC50) for virus infection or binding to host cells at micromolar 
levels (57, 75, 76). Here, based on a different experimental 
approach, we report the identification of a peptide that affects 
DENV infectivity with an IC50 in nanomolar concentration range. 
In contrast to previous approaches, our results demonstrate that, 
besides having a direct effect on the host cell/virus interaction, 
such peptides may be amenable to generated protective antibody 
responses and therefore find both prophylactic and therapeutic 
applications.
Epitope mapping based on linear peptides has been a routine 
technique for the characterization of both monoclonal and 
specific polyclonal antibodies. The antibody immunosignature 
approach relies on the use of random peptides microarrays that 
broader the epitope screening inasmuch not specific to a patho­
gen or a vaccine, resulting in reduced cost and time. In addition, 
random peptides can be reactive with antibodies directed against 
conformational epitopes, which are not possible with conven­
tional peptide microarray (40, 76). In fact, our data showed that 
even without the specific EDIII sequences on the array it was 
possible to detect DENV neutralizing peptide demonstrating the 
applicability of this technique.
In conclusion, our results demonstrated that LT and LTB 
enhance both the magnitude and the specificity of the antibody 
responses elicited in mice immunized with an anti­DENV subu­
nit vaccine, promoting changes to the epitope­binding profiles 
that, in turn, lead to enhanced virus­neutralization effects with 
regard to alum. Such findings bring relevant insights into the 
design of vaccine formulations based on purified proteins and the 
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induction of antibodies capable of preventing infections associ­
ated with different pathogens.
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